• Human Intestinal Organoids: A Tunable Balance

  2026-10-12

  Yang and colleagues report a human small-intestinal organoid strategy intended to maintain stem-cell self-renewal while increasing differentiated cell diversity. The study combines pathway-level modulation to shift organoid cell fate, but its findings should not be interpreted as evidence that DMH1 or any specific commercial compound was used, nor as proof of clinical relevance.

• DIDS, Cell Death, and Metastatic States

  2026-10-12

  The 2022 Cell Reports study by Conod, Silvano, and Ruiz i Altaba proposes that tumor cells surviving an impending-death state can acquire prometastatic properties, while DIDS appears in the broader apoptosis-survival context rather than as an established driver or treatment for this phenomenon.

• Cy3 TSA for Translational Atherosclerosis Research

  2026-10-10

  A mechanistic and strategic analysis of how tyramide signal amplification can support spatial validation of NLRP3-centered atherosclerosis research, while clarifying the evidence boundaries of fluorescence imaging and the translational role of the Cy3 TSA Fluorescence System Kit.

• High Viscosity, P-gp, and Cancer Chemoresistance

  2026-10-09

  A 2026 study links elevated extracellular fluid viscosity with doxorubicin resistance through a mechanosensitive TRPV4–YAP pathway that increases P-glycoprotein expression. Its findings extend drug resistance research beyond biochemical cues by connecting tumor fluid mechanics, membrane tension, and transporter-mediated drug efflux, while remaining primarily an in vitro mechanistic framework.

• Necrostatin-1: Evidence, Mechanism, and Limits

  2026-10-09

  A source-grounded overview of Necrostatin-1 as a RIP1 kinase inhibitor, explaining its mechanistic rationale, interpretation in a cough-variant asthma study, evidence quality, and limits for broader necroptosis and disease research.

• Necrostatin-1 in RIP1 Kinase and Necroptosis Research

  2026-10-08

  A source-grounded overview of Necrostatin-1 as a RIP1 kinase research probe, including its conceptual relevance to necroptosis, inflammatory injury, acute kidney injury research, and a recent Toxoplasma gondii virulence study. The evidence, provenance, applicability boundaries, and limitations of pharmacological interpretation are distinguished throughout.

• MSC, NRF2–ATF4, and Ferroptosis in PDAC

  2026-10-08

  A 2026 study shows that Se-methylselenocysteine (MSC) produces phenotype-dependent redox remodeling in pancreatic ductal adenocarcinoma, with KYAT1 expression influencing cellular responsiveness. Its findings connect NRF2 and ATF4 stress signaling with ferroptosis-associated changes, while also showing that transcriptomic activation does not occur uniformly across PDAC models.

• Salvianolic Acid B in Pulmonary Fibrosis Research

  2026-10-07

  Salvianolic acid B, also known as Dan Shen Suan B, is being investigated as a research compound for pulmonary fibrosis through its reported effects on LH2-associated collagen cross-linking. Current evidence is mechanistically promising but remains preclinical, with important uncertainties involving selectivity, pharmacology, model relevance, and human efficacy.

• Euglena Biohybrid Microrobots for Tumor Targeting

  2026-10-07

  Gong et al. report a magnetically guided biohybrid microrobot built around the soft, deformable microalga Euglena gracilis. The platform combines magnetic steering, adaptive deformation, autonomous tumor-directed behavior, and intrinsic chlorophyll-associated therapeutic functions, while the available evidence remains preclinical and model-based.

• Ivacaftor During Prolonged CFTR Modulator Exposure

  2026-10-06

  Shaughnessy and colleagues examined why ivacaftor remains clinically valuable despite earlier in vitro reports of reduced corrected F508del-CFTR function after prolonged exposure. Their findings indicate that, within a tezacaftor/elexacaftor background, ivacaftor increases constitutive CFTR-mediated activity, helping explain the net benefit of the triple-modulator approach.

• Deferoxamine Mesylate in Iron-Stress Research

  2026-10-06

  Deferoxamine mesylate is an iron-chelating agent relevant to research on iron availability, oxidative stress and hypoxia signaling. A 2025 Cell Reports study identified TCF25 as a regulator connecting glucose starvation, lysosomal acidification, ferritinophagy and lysosome-dependent cell death. This overview compares those findings with supplier-described applications of deferoxamine, including HIF-1α stabilization, wound healing promotion and tumor growth inhibition in breast cancer, while emphasizing that the cited study did not directly test deferoxamine.

• Obeticholic Acid: From FXR Biology to Translation

  2026-10-05

  A mechanism-first perspective on Obeticholic Acid and FXR biology, connecting bile acid regulation with liver fibrosis research while defining the evidence boundaries for translational interpretation.

• Ionizing Radiation and Altered Neuronal Differentiation

  2026-10-05

  Eom et al. reported that ionizing radiation promoted neurite outgrowth and neuronal marker expression in C17.2 mouse neural stem-like cells while producing an altered receptor-expression profile. The study connected these effects to PI3K-STAT3-mGluR1 and PI3K-p53 signaling, offering a mechanistic framework for studying radiation-associated neural dysfunction without establishing direct clinical causation.

• Pterostilbene and BBB Protection After Ischemic Stroke

  2026-10-04

  A 2023 Food & Function study examined how pterostilbene protects the blood–brain barrier after cerebral ischemia/reperfusion by addressing both early endothelial cytoskeletal disruption and later basement-membrane degradation. Its combined in vivo, in vitro, machine-learning, docking, and protein-analysis framework supports a staged mechanism involving actin-regulatory changes, Wnt signaling, and MMP-9 suppression, while leaving important questions about translation and causal specificity.

• AMPK, ULK1, and Autophagy Under Energy Stress

  2026-10-03

  Park, Lee, and Kim challenge the prevailing view that AMPK broadly promotes autophagy during glucose deprivation. Their findings support a context-dependent model in which AMPK restrains ULK1-driven autophagy during acute energy crisis while preserving the autophagy machinery for recovery after stress subsides.

7934 records 1/529 page Next 12345 下5页 Last page